Bernhard Mraz
Novartis (Austria)(AT)
Publications by Year
Research Areas
Health Systems, Economic Evaluations, Quality of Life, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Pharmaceutical Economics and Policy, Renal cell carcinoma treatment
Most-Cited Works
- → Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT(2020)20 cited
- → Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies(2015)20 cited
- → Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria(2020)13 cited
- → Quality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert Consensus(2022)12 cited
- → Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study(2019)11 cited
- → A national evaluation analysis and expert interview study of real-world data sources for research and healthcare decision-making(2024)4 cited
- → Dabrafenib plus trametinib in unselected advanced BRAF V600–mut melanoma: a non-interventional, multicenter, prospective trial(2023)3 cited
- → REACHAUT: First-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) in the real-world setting.(2019)3 cited
- → 195P REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis(2022)3 cited
- → Abstract PO3-16-10: Real-world outcomes with first-line ribociclib + endocrine therapy in patients with metastatic HR+, HER2– breast cancer: Fourth interim analysis of REACH AUT trial(2024)2 cited